1999
DOI: 10.1016/s0046-8177(99)90244-7
|View full text |Cite
|
Sign up to set email alerts
|

Neuroectodermal differentiation in Ewing's sarcoma family of tumors does not predict tumor behavior

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3

Citation Types

0
35
0
12

Year Published

2001
2001
2014
2014

Publication Types

Select...
7
1

Relationship

0
8

Authors

Journals

citations
Cited by 102 publications
(47 citation statements)
references
References 24 publications
0
35
0
12
Order By: Relevance
“…23 Our findings are in agreement with these clinical observations in which neural differentiation was not found to be associated with a major change in clinical outcome. 22 In summary, Notch signaling is active in Ewing sarcoma human tumors and cell lines. Its inhibition induces neural differentiation.…”
Section: Discussionmentioning
confidence: 98%
See 1 more Smart Citation
“…23 Our findings are in agreement with these clinical observations in which neural differentiation was not found to be associated with a major change in clinical outcome. 22 In summary, Notch signaling is active in Ewing sarcoma human tumors and cell lines. Its inhibition induces neural differentiation.…”
Section: Discussionmentioning
confidence: 98%
“…21 There is variability in the degree to which Ewing tumors exhibit a neural phenotype. 22,23 Notch signaling could be a factor responsible for the regulation of the neural phenotype in Ewing tumors. Given the development of pharmacological agents that modulate Notch signaling, modulating this pathway has potential therapeutic implications.…”
mentioning
confidence: 99%
“…The overall 5-year survival rates for localized and metastatic tumours range from 65% to 74% and 25% to 45%, respectively. 5,6 Tumours arising from the paraspinal region and scapular areas respond better to treatment, while abdominal and pelvic PNETs respond poorly. 7 a c b Figure 1 Ultrasonography (a) and Doppler scan (b) of the left chin revealed a well-defined heterogeneous hypoechoic mass at masseter region.…”
Section: Discussionmentioning
confidence: 99%
“…For example, cytokeratin subsets, especially CK7 and 19, 3,9,14 bcl-2, 15 CD56, 9 calponin, 16 beta-catenin, 17 and matrix metalloproteinase-2 (MMP-2) 18 have been reported as potentially useful in synovial sarcoma; p75 nerve growth factor receptor (NGFR), 19 nestin, 20 CD57, 7,21,22 CD34, 22 PGP9.5, 23 and GFAP 21 in malignant peripheral nerve sheath tumor; Fli-1 in Ewing sarcoma; 6 and neuroectodermal markers such as chromoganin, synaptophysin, and PGP9.5 in primitive neuroectodermal tumor. [24][25][26][27] In order to further characterize the immunohistochemical profiles of synovial sarcoma, malignant peripheral nerve sheath tumor, and Ewing sarcoma in a model that mimics small biopsy sampling, we evaluated a series of 73 tumors in tissue microarrays with a panel of 22 antibodies potentially useful in the differential diagnosis. We then analyzed the data with hierarchical cluster analysis, a mathematical technique employed for analyzing large data sets, most often used for gene arrays.…”
mentioning
confidence: 99%